An Effective Non-Drug Option Submitting to FDA for Clearance in the Management of Pain, Sleep, and Anxiety
Sponsored by Sana Health
This activity is not certified for credit.
Date
Wednesday, September 8
Start Time
10:30a
End Time
11:20a
Room
Brera Ballrom
Level 3
Program Description
Learning objectives:
• Participants will understand the limitations of existing therapies for pain conditions exacerbated by anxiety and learn about Sana's emerging non-drug wearable therapy device.
• Participants will understand that the Sana device is already available to their patients under a 513(g) Wellness label, and anticipating to be FDA-cleared for Fibromyalgia by the end of this year.
• Pain Week attendees can experience a 16-minute Sana session at Sana Health's booth
"Sana gave me my life back" -Joyce, Sana user diagnosed with Fibromyalgia
Sana is an at-home use, audio-visual neuromodulation device that produces a deep state of relaxation on demand. Results of our pivotal study at Duke University, for the treatment of Fibromyalgia, will be released at Pain Week.
Fibromyalgia, a chronic pain condition that often has no clear cause, affects 4 million people in the US. Standard treatments like pregabalin, duloxetine, and milnacipran have limited efficacy for many patients and can have intolerable side effects. In this Spotlight session with Sana Health, pain psychology expert Martin Cheatle, PhD will discuss treatment considerations for fibromyalgia and associated conditions and review early data from Sana Health's pivotal clinical trial at Duke University School of Medicine. Sana Health CEO Richard Hanbury will share the story of how he developed the Sana device and overcame chronic pain after a life-threatening accident.
Faculty
Christopher Rhyne, MD
Pre-event Registration
No preregistration required
Refreshments will be served
Contact Name
Erin G Friedman
Contact Phone
(406) 370-0829
Contact email
[email protected]